Researchers report development of weekly diabetes treatment
08 Sep 2008

A new once-weekly method for the treatment of Type 2 diabetes could replace the more common twice-daily injection, a new study has suggested.

Published in the Lancet journal and carried out by staff at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in New York, USA, the study notes there is currently no available therapy for patients with the condition which can be received once per week.

The researchers state the treatment - called Exenatide - mimics the action of glucagon-like peptide 1 and the study compared outcomes for patients self-injecting the drug once per week against the traditional 14 injections per week.

In a study involving 300 patients which lasted six months, it was found that 75 per cent of participants who received Exenatide experienced fewer side effects, had no increased risk of hypoglycaemia and were able to control their diabetes - as defined by reaching target glucose levels.

"This is an excellent example of moving discovery through to therapeutic application," comments Dr Jim Woodgett, director of research at the Samuel Lunenfeld Research Institute.

Print Article    Bookmark

• Porridge could limit type-2 diabetes side effects 09/01/09
• Men with type-2 diabetes at greater risk of cardiovascular death 06/01/09
• Decline in mental processing affects diabetes patients, study reveals 05/01/09
• Leptin study could lead to new diabetes treatment 23/12/08
• Symptomless virus linked with type 1 diabetes 19/12/08

• PRANDIN Tablets - 49.44%
  ... in patients with Type 2 diabetes (Non Insulin-Dependent Diabetes Mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in Type 2 diabetes patients who are not ...
  
  
• DDAVP - 49.42%
  ... and treatment of vasopressin-sensitive cranial diabetes insipidus; establishing renal concentration capacity. DDAVP Tablets: Treatment of vasopressin-sensitive cranial diabetes insipidus; treatment of post-hypophysectomy polyuria/ polydipsia. DDAVP/Desmopressin Injection: Cranial diabetes insipidus ...
  
  
• JANUVIA Film-Coated Tablets - 47.95%
  JANUVIA is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin when diet and exercise, plus metformin do not provide adequate glycaemic control. For patients with type 2 diabetes mellitus in whom use of a PPAR? agonist (i.e. a ...
  
  
• EXUBERA - 47.95%
  ... for the treatment of adult patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic agents and requiring insulin therapy. EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, in addition to long or intermediate acting ...
  
  
• NOCUTIL - 47.95%
  Treatment of idiopathic central diabetes insipidus, or diabetes insipidus occurring after hypophysectomy, cranial trauma, or surgery in the pituitary region ...
  
  
• GLUCOPHAGE - 47.95%
  Non-insulin dependent (type II) diabetes either alone or with sulphonylureas. Adjuvant therapy in insulin-dependent diabetes, particularly in the obese ...